4.1300
-0.4900
(-10.61%)
At close: April 10 at 4:00:02 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Cash Flow
-32,845
-32,845
19,349
-20,121
-26,266
Investing Cash Flow
-69,739
-69,739
-65,568
22,299
-64,968
Financing Cash Flow
109,001
109,001
56,176
-1,239
79,839
End Cash Position
21,943
21,943
15,526
5,569
4,630
Income Tax Paid Supplemental Data
--
--
450
--
--
Interest Paid Supplemental Data
--
--
150
225
222
Capital Expenditure
-514
-514
-414
-118
-168
Issuance of Capital Stock
108,211
108,211
60,138
--
79,726
Repayment of Debt
--
--
-3,750
-1,250
--
Repurchase of Capital Stock
--
--
-28
-4
--
Free Cash Flow
-33,359
-33,359
18,935
-20,239
-26,434
12/31/2021 - 4/5/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
AARD Aardvark Therapeutics, Inc. Common Stock
7.02
-9.88%
SEPN Septerna, Inc.
5.16
-8.02%
MBX MBX Biosciences, Inc.
6.27
-2.03%
UPB Upstream Bio, Inc.
6.40
-1.99%
BCAX Bicara Therapeutics Inc.
10.15
-2.40%
BOLD Boundless Bio, Inc.
1.1900
-0.83%
SION Sionna Therapeutics, Inc.
7.66
-13.74%
SYRE Spyre Therapeutics, Inc.
11.93
-10.77%
MAZE Maze Therapeutics, Inc.
7.60
-4.64%
XNCR Xencor, Inc.
7.92
-10.10%